BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liu G, Wang Q, Shi Y, Peng X, Liu H, Peng Y, He L. Resveratrol Attenuates Adriamycin-Induced Focal Segmental Glomerulosclerosis through C3aR/C5aR- Sphingosine Kinase 1 Pathway. Pharmacology 2017;100:253-60. [DOI: 10.1159/000479525] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Janneh AH, Ogretmen B. Targeting Sphingolipid Metabolism as a Therapeutic Strategy in Cancer Treatment. Cancers (Basel) 2022;14:2183. [PMID: 35565311 DOI: 10.3390/cancers14092183] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Xu H, Wu T, Huang L. Therapeutic and delivery strategies of phytoconstituents for renal fibrosis. Adv Drug Deliv Rev 2021;177:113911. [PMID: 34358538 DOI: 10.1016/j.addr.2021.113911] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
3 Espinoza JL, Kurokawa Y, Takami A. Rationale for assessing the therapeutic potential of resveratrol in hematological malignancies. Blood Rev 2019;33:43-52. [PMID: 30005817 DOI: 10.1016/j.blre.2018.07.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
4 Huwiler A, Pfeilschifter J. Sphingolipid signaling in renal fibrosis. Matrix Biol 2018;68-69:230-47. [PMID: 29343457 DOI: 10.1016/j.matbio.2018.01.006] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
5 Wang F, Huang LP, Yang P, Ye LP, Wu C, Zhu QX. Inflammatory kidney injury in trichloroethylene hypersensitivity syndrome mice: Possible role of C3a receptor in the accumulation of Th17 phenotype. Ecotoxicol Environ Saf 2019;186:109772. [PMID: 31614297 DOI: 10.1016/j.ecoenv.2019.109772] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
6 Gao S, Cui Z, Zhao MH. The Complement C3a and C3a Receptor Pathway in Kidney Diseases. Front Immunol 2020;11:1875. [PMID: 32973774 DOI: 10.3389/fimmu.2020.01875] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]